Biotech Values

[randychub]

Are we splitting statistical hairs in looking at averages across N=6 populations?


There is a very obvious reason that clincal trial are not run with 6 patients. If a fair number of these six patients vision continued to decline I would be worried. If 2 out of 6 patients had 5-6 lines of improvement I would be surprised simply because with the size of the eyet trial and the lack of the number of patients with similiar benefit.

They eyet trial had 809 patients that received macugen. Of those only 6 patients had >=+3 lines of vision improvement. I'am assuming no one had greater then 3 lines or they would have mentioned that fact. Somone correct me if I'am wrong.

In the mexio trials with just 40 patients we seen 10 patients with >=+ 3 lines of vision with no maintence therapy just 4 weeks of treatment

In the most recently completed 40mg trial, in the 2nd eye 2 patients had >=+ 3 lines of vision.

In the 10mg trial, i can't find the press release but I believe 1 patient had vision improvement of >=+ 3 lines of vision.

That makes 13 out of 52 patients compared to 6 out of 809. I'll take squalamine with my amd please.

Randy